INTEGRAGEN (ALINT.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALINT - FR0010908723 - Common Stock
ALINT.PA Key Statistics, Chart & Performance
The current stock price of ALINT.PA is 0.139 EUR. In the past month the price decreased by -4.55%. In the past year, price decreased by -83.35%.
ALINT.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 65.04 | 42.77B | ||
| ARGX.BR | ARGENX SE | 62.9 | 41.36B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.69B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.09B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.64B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.88B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.85B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| NANO.PA | NANOBIOTIX | N/A | 831.23M | ||
| IVA.PA | INVENTIVA SA | N/A | 841.43M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 19.82 | 660.82M |
Related stock screener links
About ALINT.PA
Company Profile
IntegraGen SA engages in the development of genetic biomarkers. The company is headquartered in Evry, Ile-De-France and currently employs 39 full-time employees. The company went IPO on 2010-06-18. The company researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. The company uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). The company also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The firm also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.
Company Info
INTEGRAGEN
Genopole Campus 1 - Genavenir 8 5 Rue Henri Desbrueres
Evry ILE-DE-FRANCE FR
Employees: 44
Phone: 33160910900
INTEGRAGEN / ALINT.PA FAQ
What does ALINT do?
IntegraGen SA engages in the development of genetic biomarkers. The company is headquartered in Evry, Ile-De-France and currently employs 39 full-time employees. The company went IPO on 2010-06-18. The company researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. The company uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). The company also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The firm also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.
Can you provide the latest stock price for INTEGRAGEN?
The current stock price of ALINT.PA is 0.139 EUR. The price increased by 1.83% in the last trading session.
Does INTEGRAGEN pay dividends?
ALINT.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALINT stock?
ALINT.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the next earnings date for ALINT stock?
INTEGRAGEN (ALINT.PA) will report earnings on 2026-04-27.
ALINT.PA Technical Analysis
ALINT.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALINT.PA. While ALINT.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ALINT.PA Financial Highlights
Over the last trailing twelve months ALINT.PA reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS decreased by -2200% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.94% | ||
| ROE | -442.86% | ||
| Debt/Equity | 0 |